Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.75 |
| ▸ | CD38 | P28907 | 1/20 | 0.65 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.63 |
| ▸ | FBP1 | P09467 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.63 |
| ▸ | TEK | Q02763 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923578 | 0.86 | EGFR (1.00) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL31299934 | 0.86 | EGFR (1.00) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL6188729 | 0.86 | EGFR (0.77) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL2991833 | 0.86 | EGFR (1.00) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL28471823 | 0.85 | KDM4E (0.72) | EGFRCD38GRM1ERBB2KDR | |
| SCHEMBL3004196 | 0.85 | EGFR (0.54) | EGFRCD38ERBB2KDRRAF1 | |
| Hydrochloric Acid SCHEMBL6190330 | 0.85 | EGFR (0.75) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL21083167 | 0.85 | EGFR (0.75) | EGFRCD38GRM1ERBB2FBP1 | |
| SCHEMBL641359 | 0.85 | EGFR (0.75) | EGFRCD38GRM1ERBB2FBP1 | |
| Hydrochloric Acid SCHEMBL7764930 | 0.85 | EGFR (0.97) | EGFRCD38GRM1ERBB2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106317026-A | Compounds capable of inhibiting ErbB/HDAC and preparation method thereof, and pharmaceutical composition comprising compounds and application thereof | 清华大学深圳研究生院 | 2017-01-11 | — | — | CN | disclosed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014063631-A1 | TYROSINE KINASE IRREVERSIBLE INHIBITOR AND PREPARATION METHOD AND APPLICATIONS THEREOF | ZHANG JIANCUN (CN) | 2014-05-01 | — | — | WO | disclosed |
| CN-101367794-B | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-102911163-A | Quinazoline derivatives, composition containing derivatives and pharmaceutical application of derivatives | Hangzhou minsheng pharmaceutical co ltd | 2013-02-06 | — | — | CN | disclosed |
| US-8318932-B2 | Process for producing 4-aminoquinazoline compound | UBE INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-1481971-B1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131610-A1 | HEAT TRANSFER MEDIUM BASED ON SULPHUR AND USE OF THE HEAT TRANSFER MEDIUM | SIEMENS AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | WO | disclosed |
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | disclosed |
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| CN-101367794-A | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-02-18 | — | — | CN | disclosed |
| US-20080177069-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | UBE INDUSTRIES, LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1481971-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | Ube Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | HRH4, CYP3A4, HRH3 | EGFR 1101/4885CD38 3171/4885GRM1 1237/4885 |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | LCK, ZAP70, FYN | EGFR 24/4885CD38 4460/4885GRM1 2701/4885 |
| US-20080177069-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | HRH4, CYP3A4, HRH3 | EGFR 1101/4885CD38 3171/4885GRM1 1237/4885 |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | HRH4, HRH3, H1-4 | EGFR 543/4885CD38 3243/4885GRM1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.